Key Highlights
- Worldwide agreement worth up to $380M includes capacity reservation and supply for CAR T cell therapies.
- Cellares to use its Cell Shuttle™ and Cell Q™ systems for exclusive Bristol Myers Squibb production.
- The collaboration aims to expand manufacturing capacity and reduce therapy turnaround times.
Source: Direct
Notable Quotes
- “Our collaboration with Cellares strengthens our existing internal manufacturing capabilities for CAR T cell therapies by giving us access to the first end-to-end fully automated cell therapy manufacturing platform,” – Lynelle B. Hoch, President, Cell Therapy Organization at Bristol Myers Squibb
- “We look forward to demonstrating how our innovative technology’s emphasis on standardization will accelerate commercial-scale manufacturing and worldwide deployment,” – Fabian Gerlinghaus, CEO and Co-founder at Cellares
SoHC's Take
This strategic partnership between Bristol Myers Squibb and Cellares could significantly shape the future of cell therapy manufacturing. By leveraging Cellares’ automated and scalable platforms, Bristol Myers Squibb not only enhances its production capacities but also potentially improves the availability and speed of delivering life-saving treatments globally. The deal emphasizes automation and standardization as crucial for meeting the growing demand for cell therapies, aligning with industry trends towards more efficient biopharmaceutical production processes. As both companies continue to invest in innovative manufacturing technologies, this agreement might set a new standard for the industry and accelerate the broader adoption of CAR T cell therapies.
